Direct Vasoactive Effects of the Chromogranin A (CHGA) Peptide Catestatin in Humans In Vivo

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:DiVA.org:uu-134167" > Direct Vasoactive E...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Fung, Maple M. (author)

Direct Vasoactive Effects of the Chromogranin A (CHGA) Peptide Catestatin in Humans In Vivo

Article/chapterEnglish2010

Publisher, publication year, extent ...

2010-07-27
Informa UK Limited,2010
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:uu-134167
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-134167URI
https://doi.org/10.3109/10641960903265246DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Catestatin is a bioactive peptide of chromogranin A (CHGA) that is co-released with catecholamines from secretory vesicles. Catestatin may function as a vasodilator and is diminished in hypertension. To evaluate this potential vasodilator in vivo without systemic counterregulation, we infused catestatin to target concentrations of similar to 50, similar to 500, similar to 5000 nM into dorsal hand veins of 18 normotensive men and women, after pharmacologic venoconstriction with phenylephrine. Pancreastatin, another CHGA peptide, was infused as a negative control. After preconstriction to similar to 69%, increasing concentrations of catestatin resulted in dose-dependent vasodilation (P = 0.019), in female subjects (to similar to 44%) predominantly. The EC50 (similar to 30 nM) for vasodilation induced by catestatin was the same order of magnitude to circulating endogenous catestatin (4.4 nM). No vasodilation occurred during the control infusion with pancreastatin. Plasma CHGA, catestatin, and CHGA-to-catestatin processing were then determined in 622 healthy subjects without hypertension. Female subjects had higher plasma catestatin levels than males (P = 0.001), yet lower CHGA precursor concentrations (P = 0.006), reflecting increased processing of CHGA-to-catestatin (P < 0.001). Our results demonstrate that catestatin dilates human blood vessels in vivo, especially in females. Catestatin may contribute to sex differences in endogenous vascular tone, thereby influencing the complex predisposition to hypertension.

Subject headings and genre

catestatin
chromogranin A
vasodilation
veins
MEDICINE
MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

Salem, Rany M. (author)
Mehtani, Parag (author)
Thomas, Brenda (author)
Lu, Christine F. (author)
Perez, Brandon (author)
Rao, Fangwen (author)
Stridsberg, MatsUppsala universitet,Biokemisk endokrinologi(Swepub:uu)matsstri (author)
Ziegler, Michael G. (author)
Mahata, Sushil K. (author)
O'Connor, Daniel T. (author)
Uppsala universitetBiokemisk endokrinologi (creator_code:org_t)

Related titles

In:Clinical and experimental hypertension (1993, Print): Informa UK Limited32:5, s. 278-2871064-19631525-6006

Internet link

Find in a library

Clinical and experimental hypertension (1993, Print) (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Fung, Maple M.; Salem, Rany M.; Mehtani, Parag; Thomas, Brenda; Lu, Christine F.; Perez, Brandon; show more...; Rao, Fangwen; Stridsberg, Mats; Ziegler, Michael ...; Mahata, Sushil K ...; O'Connor, Daniel ...; show less...

Articles in the publication: Clinical and exp ...

By the university: Uppsala University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se